Revelation Biosciences(US:REVB)2026-02-26 21:25Financial Performance - Net loss for the three months ended December 31, 2025 was $2.5 million, or $(1.65) per share, compared to a net loss of $1.7 million, or $(59.76) per share for the same period in 2024[5] - Net loss for the year ended December 31, 2025 was $8.9 million, or $(23.95) per share, compared to a net loss of $15.0 million, or $(1,052.16) per share for the year ended December 31, 2024[5] - Total operating expenses for the year ended December 31, 2025 were $9.1 million, up from $8.0 million in 2024[12] Cash Position - As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, an increase from $6.5 million as of December 31, 2024[4] - Net cash used for operating activities for the twelve months ended December 31, 2025 was $8.3 million, a significant decrease from $18.3 million for the same period in 2024[5] - The company believes its current cash and cash equivalents are sufficient to fund operations into the first quarter of 2027[4] Clinical Developments - Revelation announced positive results from the PRIME Clinical Study in late-stage chronic kidney disease patients[7] - Revelation is developing Gemini as a treatment for acute kidney injury and chronic kidney disease, with ongoing clinical evaluations[6] Equity Position - Total stockholders' equity increased to $8.9 million as of December 31, 2025, compared to $4.7 million in 2024[14] - The company received net proceeds of $6.7 million from a warrant inducement in January 2026[7]